

# FOUNTAINHEAD CAPITAL PARTNERS

*Providing Advice and Funding Solutions for Growth Companies*

## **FOUNTAINHEAD COMPLETES BIOTECH REVERSE MERGER – BUILDING ON TREND IN THE BIOTECH SPACE FOR COMPANIES TO ACCESS THE PUBLIC MARKETS THROUGH THE ACCELERATED IPO MECHANISM**

### **Arno Therapeutics, Inc. Completes \$18 Million Financing and Reverse Merger with Laurier International, Inc. a Fountainhead Controlled Public Company-June 2 2008**

Arno Therapeutics (Arno) is a biopharmaceutical company that acquires the rights to research and commercially develop innovative products for the treatment of cancer. Arno's lead product, AR-67, is a novel, third-generation camptothecin analogue that has exhibited high potency and improved pharmacokinetic properties compared with first- and second-generation camptothecin analogues. In addition, Arno is developing two novel, preclinical compounds: AR-12, which is a novel inhibitor of phosphoinositide dependent protein kinase-1 (PDK-1); and AR-42, which is a novel histone deacetylase (HDAC) inhibitor.

Arno is committed to developing all aspects of its product candidates, as well as pursuing additional in-licensing opportunities. Arno is actively pursuing additional compounds to expand its portfolio.

Arno merged with Laurier International, Inc., a publicly traded company controlled by Fountainhead currently traded under the ticker symbol "LRRI.OB". Arno will continue to trade under the symbol LRRI.OB until such time as it receives a new symbol.

#### **Our contact details**

##### **Fountainhead Capital Partners**

Portman House  
Hue Street St. Helier  
Jersey JE4 5RP  
Channel Islands  
Tel: +44 1534 626141  
Fax: +44 1534 630113  
Email: [info@fhcpartners.com](mailto:info@fhcpartners.com)

##### **David Cantor**

E-mail: [david.cantor@fhcpartners.com](mailto:david.cantor@fhcpartners.com)

##### **Craig Kirsch**

E-mail: [craig.kirsch@fhcpartners.com](mailto:craig.kirsch@fhcpartners.com)

##### **Adrian Liddell**

Email: [adrian.liddell@fhcpartners.com](mailto:adrian.liddell@fhcpartners.com)

##### **Peter Zachariou**

Email: [peterz@fhcpartners.com](mailto:peterz@fhcpartners.com)

#### **About Fountainhead Capital Partners**

Fountainhead Capital Partners Limited is an investment group based in Jersey, Channel Islands with partners based in the US and Europe. We invest in and raise funds for businesses that have a demonstrable growth story or niche market position. In the last two years we have been involved in 9 transactions raising over \$200 million.

Fountainhead generally invests through an Alternative Public Offering structure that combines a reverse merger with an OTCBB Public Vehicle controlled by Fountainhead and a simultaneous PIPE funding. Recent transactions we have been involved in include: Sino Shipping, a reverse merger to create a Chinese shipping group; NovaRay, a \$10m funding for an innovative developer of revolutionary digital x-ray technology for medical imaging; and Nile Therapeutics, a \$20m funding for a clinical stage biopharmaceutical company developing innovative product for the treatment of cardiovascular disease

Fountainhead's role has varied from originator of the opportunity, investing in and raising capital (both in partnership with an investment bank and on our own), to purely providing the public vehicle for the transaction.

**Actions speak louder than words so please contact us should you have a growth company that needs assistance in achieving its goals.**